These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10066888)

  • 41. Prostate cancer associated with CYP17 genotype.
    Wadelius M; Andersson AO; Johansson JE; Wadelius C; Rane E
    Pharmacogenetics; 1999 Oct; 9(5):635-9. PubMed ID: 10591544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CYP17A1: a biochemistry, chemistry, and clinical review.
    Porubek D
    Curr Top Med Chem; 2013; 13(12):1364-84. PubMed ID: 23688130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
    Padmakar Darne C; Velaparthi U; Saulnier M; Frennesson D; Liu P; Huang A; Tokarski J; Fura A; Spires T; Newitt J; Spires VM; Obermeier MT; Elzinga PA; Gottardis MM; Jayaraman L; Vite GD; Balog A
    Bioorg Med Chem Lett; 2022 Nov; 75():128951. PubMed ID: 36031020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
    Njar VC; Brodie AM
    J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17).
    Blass BE; Iyer P; Abou-Gharbia M; Childers WE; Gordon JC; Ramanjulu M; Morton G; Arumugam P; Boruwa J; Ellingboe J; Mitra S; Reddy Nimmareddy R; Paliwal S; Rajasekhar J; Shivakumar S; Srivastava P; Tangirala RS; Venkataramanaiah K; Bobbala R; Yanamandra M; Krishnakanth Reddy L
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2270-2274. PubMed ID: 29803730
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytochrome P450 17alpha hydroxylase/17,20 lyase (CYP17) function in cholesterol biosynthesis: identification of squalene monooxygenase (epoxidase) activity associated with CYP17 in Leydig cells.
    Liu Y; Yao ZX; Papadopoulos V
    Mol Endocrinol; 2005 Jul; 19(7):1918-31. PubMed ID: 15761033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
    Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
    Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
    J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
    Wang M; Fang Y; Gu S; Chen F; Zhu Z; Sun X; Zhu J
    Eur J Med Chem; 2017 May; 132():157-172. PubMed ID: 28350999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
    J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase/C17,20-lyase.
    Duc I; Bonnet P; Duranti V; Cardinali S; Rivière A; De Giovanni A; Shields-Botella J; Barcelo G; Adje N; Carniato D; Lafay J; Pascal JC; Delansorne R
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):537-42. PubMed ID: 12767278
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
    Tigli H; Yazici H; Dalay N
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.
    Ferraldeschi R; Sharifi N; Auchus RJ; Attard G
    Clin Cancer Res; 2013 Jul; 19(13):3353-9. PubMed ID: 23470964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
    Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
    Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigations on inhibitors of human 17 alpha-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17 alpha-hydroxylase-17,20-lyase, Part II.
    Schappach A; Höltje HD
    Pharmazie; 2001 Nov; 56(11):835-42. PubMed ID: 11817165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.
    Alex AB; Pal SK; Agarwal N
    Ther Adv Med Oncol; 2016 Jul; 8(4):267-75. PubMed ID: 27482286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
    Drăgan CA; Hartmann RW; Bureik M
    J Enzyme Inhib Med Chem; 2006 Oct; 21(5):547-56. PubMed ID: 17194026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
    Krug SJ; Hu Q; Hartmann RW
    J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.